Expression of FGL2 in Colon Cancer and its Clinical Significance
10.3969/j.issn.1008.7125.2022.09.006
- Author:
Xianglian ZHANG
1
;
Xingfen WANG
1
;
Yiwen XING
1
;
Miao YU
1
;
Zhiqiang WANG
2
Author Information
1. Department of Pathology, the Second Hospital of Tianjin Medical University
2. Department of Anorectal Diseases, the Second Hospital of Tianjin Medical University
- Publication Type:Journal Article
- Keywords:
Colonic Neoplasms;
Fibrinogen-Like Protein 2;
Immune Cells, Tumor Infiltrating;
Tumor Microenvironment
- From:
Chinese Journal of Gastroenterology
2022;27(9):554-557
- CountryChina
- Language:Chinese
-
Abstract:
Background: Colorectal cancer is one of the most commonly diagnosed cancer and leading causes of cancer death worldwide. Fibrinogen-like protein 2 (FGL2), a member of the fibrinogen family, has been demonstrated as a regulator of immune cell functions in tumor microenvironment and might facilitate tumor progression. Aims: To study the expression and clinical significance of FGL2 in colon cancer. Methods: One hundred and fifty colon cancer patients diagnosed from January 2018 to January 2022 at the Second Hospital of Tianjin Medical University were enrolled in this study. The paraffin-embedded tissues were collected for detection of FGL2 protein and the surface markers of tumor infiltrating immune cells (TIICs), including CD4, CD8, CD20, CD68, and CD56 by using immunohistochemistry. The correlations of FGL2 expression level with the clinicopathological parameters and TIICs counting were analyzed. Results: Expression of FGL2 was upregulated in 68.7% of the colon cancer cases. Its expression level was correlated positively with the tumor size and TNM staging (all P<0.05), while no correlations were found between FGL2 expression level and gender, age, tumor differentiation, and presence of vascular invasion (all P>0.05). Meanwhile, the expression level of FGL2 was associated with the cell counting of CD4
